Hepatitis C virus infection in acute leukemia with liver dysfunction.
Kawatani
T
T
Suou
T
T
Tajima
F
F
Ooi
S
S
Kawasaki
H
H
D000208:Acute Disease; D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D001803:Blood Transfusion; D005500:Follow-Up Studies; D016174:Hepacivirus; D006508:Hepatitis Antibodies / Q000097:blood; D006526:Hepatitis C / Q000150:complications* / Q000503:physiopathology / Q000628:therapy; D018937:Hepatitis C Antibodies; D006801:Humans; D007951:Leukemia, Myeloid / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D008111:Liver Function Tests; D016133:Polymerase Chain Reaction; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D012367:RNA, Viral / Q000097:blood; D013997:Time Factors
D006508:Hepatitis Antibodies; D018937:Hepatitis C Antibodies; D012367:RNA, Viral; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase; D001663:Bilirubin